Development of glioblastoma organoids and their applications in personalized therapy.

Autor: Xu C; School of Clinical Medicine, Hebei University, Department of Neurosurgery, Affiliated Hospital of Hebei University, Baoding 07100, China., Yuan X; School of Basic Medical Sciences, Hebei University, Baoding 07100, China., Hou P; School of Basic Medical Sciences, Hebei University, Baoding 07100, China., Li Z; School of Basic Medical Sciences, Hebei University, Baoding 07100, China., Wang C; School of Clinical Medicine, Hebei University, Department of Neurosurgery, Affiliated Hospital of Hebei University, Baoding 07100, China., Fang C; School of Clinical Medicine, Hebei University, Department of Neurosurgery, Affiliated Hospital of Hebei University, Baoding 07100, China.; Hebei Key Laboratory of Precise Diagnosis and Treatment of Glioma, Baoding 071000, China., Tan Y; School of Basic Medical Sciences, Hebei University, Baoding 07100, China.; Hebei Key Laboratory of Precise Diagnosis and Treatment of Glioma, Baoding 071000, China.; Department of Pathology, Affiliated Hospital of Hebei University, Baoding 07100, China.
Jazyk: angličtina
Zdroj: Cancer biology & medicine [Cancer Biol Med] 2023 Jun 05; Vol. 20 (5).
DOI: 10.20892/j.issn.2095-3941.2023.0061
Abstrakt: Glioblastomas (GBMs) are the brain tumors with the highest malignancy and poorest prognoses. GBM is characterized by high heterogeneity and resistance to drug treatment. Organoids are 3-dimensional cultures that are constructed in vitro and comprise cell types highly similar to those in organs or tissues in vivo , thus simulating specific structures and physiological functions of organs. Organoids have been technically developed into an advanced ex vivo disease model used in basic and preclinical research on tumors. Brain organoids, which simulate the brain microenvironment while preserving tumor heterogeneity, have been used to predict patients' therapeutic responses to antitumor drugs, thus enabling a breakthrough in glioma research. GBM organoids provide an effective supplementary model that reflects human tumors' biological characteristics and functions in vitro more directly and accurately than traditional experimental models. Therefore, GBM organoids are widely applicable in disease mechanism research, drug development and screening, and glioma precision treatments. This review focuses on the development of various GBM organoid models and their applications in identifying new individualized therapies against drug-resistant GBM.
Competing Interests: No potential conflicts of interest are disclosed.
(Copyright © 2023 Cancer Biology & Medicine.)
Databáze: MEDLINE
Externí odkaz: